Literature DB >> 2954599

Adrenal steroids stimulate growth and progesterone receptor levels in rat uterus and DMBA-induced mammary tumors.

P G Spinola, B Marchetti, F Labrie.   

Abstract

We have studied the effect of treatment with the adrenal steroids androst-5-ene-3 beta,17 beta-diol (delta 5-diol) and dehydroepiandrosterone (DHEA) on the growth and progesterone receptor levels of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. While the total number of tumors in ovariectomized animals was 0.60 +/- 0.19 tumor per rat after 24 days, it increased to 2.54 +/- 0.50 (p less than 0.01) and 1.42 +/- 0.26 (p less than 0.01) in the delta 5-diol and DHEA (2 mg, twice daily) treated animals, respectively. While very few new tumors developed during a 24-day period in ovariectomized animals (0.07 +/- 0.07/rat), an average of 0.47 +/- 0.19 (p less than 0.05) new tumor per animal appeared in intact rats. In ovariectomized animals treated with delta 5-diol or DHEA, the numbers of new tumors were 0.77 +/- 0.26 (p less than 0.05) and 0.42 +/- 0.15 (p less than 0.05), respectively. An even more striking effect was observed on average total tumor area, which decreased from 4.70 +/- 0.95 cm2 in intact animals to 0.75 +/- 0.27 cm2 (p less than 0.01) following ovariectomy. Values of 9.79 +/- 2.25 (p less than 0.01) and 3.93 +/- 0.86 cm2 (p less than 0.01) were found in the delta 5-diol- and DHEA-treated ovariectomized animals, respectively. Treatment of ovariectomized animals with delta 5-diol and DHEA caused a marked increase (p less than 0.01) in progesterone receptor levels in both the uteri and DMBA-induced mammary tumors. Uterine weight was also stimulated (p less than 0.01) by treatment with the two adrenal steroids.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2954599     DOI: 10.1007/bf01807337

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  26 in total

1.  Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat.

Authors:  J Asselin; F Labrie
Journal:  J Steroid Biochem       Date:  1978-11       Impact factor: 4.292

2.  MAMMARY TUMOR INDUCTION BY ESTROGEN OR ANTERIOR PITUITARY HORMONES IN OVARIECTOMIZED RATS GIVEN 7, 12-DIMETHYL-1, 2-BENZANTHRACENE.

Authors:  P K TALWALKER; J MEITES; H MIZUNO
Journal:  Proc Soc Exp Biol Med       Date:  1964-06

3.  Dehydroepiandrosterone: kinetics of metabolism in normal men and women.

Authors:  C E Bird; J Murphy; K Boroomand; W Finnis; D Dressel; A F Clark
Journal:  J Clin Endocrinol Metab       Date:  1978-10       Impact factor: 5.958

4.  Androstenediol levels in human peripheral plasma.

Authors:  R L Rosenfield; P Otto
Journal:  J Clin Endocrinol Metab       Date:  1972-12       Impact factor: 5.958

5.  Actions and interactions of delta 5-androstene-3 beta, 17 beta-diol and 17 beta-estradiol in the immature rat uterus.

Authors:  L G van Doorn; J Poortman; J H Thijssen; F Schwarz
Journal:  Endocrinology       Date:  1981-04       Impact factor: 4.736

6.  Dehydroepiandrosterone and androst-5-ene-3 beta,17 beta-diol in human mammary cancer cytosolic and nuclear compartments and their relationship to estrogen receptor.

Authors:  J B Adams; L Archibald; K Seymour-Munn
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

7.  Products of dehydroepiandrosterone metabolism by human mammary tumors and their influence on estradiol receptor binding.

Authors:  K Li; T Foo; J B Adams
Journal:  Steroids       Date:  1978-01       Impact factor: 2.668

8.  Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue.

Authors:  A A van Landeghem; J Poortman; M Nabuurs; J H Thijssen
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

9.  Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells.

Authors:  J Adams; M Garcia; H Rochefort
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

10.  Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors.

Authors:  C HUGGINS; G BRIZIARELLI; H SUTTON
Journal:  J Exp Med       Date:  1959-01-01       Impact factor: 14.307

View more
  7 in total

1.  Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.

Authors:  Mark P Thomas; Barry V L Potter
Journal:  J Med Chem       Date:  2015-06-12       Impact factor: 7.446

2.  Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate.

Authors:  E Kordon; C Lanari; R Meiss; P Elizalde; E Charreau; C Dosne Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

3.  Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors.

Authors:  P G Spinola; B Marchetti; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1988-12       Impact factor: 4.872

4.  Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.

Authors:  S Dauvois; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

5.  Dehydroepiandrosterone concentration in breast cancer tissue is related to its plasma gradient across the mammary gland.

Authors:  E Brignardello; P Cassoni; M Migliardi; A Pizzini; M Di Monaco; G Boccuzzi; M Massobrio
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

6.  Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  F Labrie; S Li; C Labrie; C Lévesque; Y Mérand
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

7.  Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).

Authors:  L W Lawrence Woo; Dharshini Ganeshapillai; Mark P Thomas; Oliver B Sutcliffe; Bindu Malini; Mary F Mahon; Atul Purohit; Barry V L Potter
Journal:  ChemMedChem       Date:  2011-08-25       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.